Literature DB >> 3510365

Nutrition, somatomedins, and the brain.

L S Phillips.   

Abstract

Conditions of decreased nutrient supply (malnutrition) and/or decreased nutrient utilization (diabetes) are attended by impairment of growth despite an increase in circulating levels of growth hormone (GH). Growth involves the actions of somatomedins, circulating insulinlike polypeptides with anabolic effects on cartilage, fat, and muscle. In malnutrition and diabetes, mechanisms of growth impairment appear to include a decrease in GH-induced generation of somatomedins, together with an increase in somatomedin inhibitors, factors which antagonize somatomedin action. Brain mediation of these alterations involves a rise in GH secretion due to decreased negative feedback from somatomedins, perhaps accentuated by blunting of feedback via actions of somatomedin inhibitors. In combination these processes lead to shunting of metabolic fuels toward vital processes and away from growth (via decreased somatomedin action) and to protein-sparing and increase in alternate metabolic fuels (via direct GH actions on muscle and fat). Further study of involved hypothalamic and pituitary mechanisms should yield additional insights into the role of the brain in metabolic homeostasis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510365     DOI: 10.1016/0026-0495(86)90100-9

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

Review 1.  Molecular biology of the insulin-like growth factors. Relevance to nervous system function.

Authors:  J E Hepler; P K Lund
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  Endocrine abnormalities in severe traumatic brain injury--a cue to prognosis in severe craniocerebral trauma?

Authors:  J M Hackl; M Gottardis; C Wieser; E Rumpl; C Stadler; S Schwarz; R Monkayo
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Clinical evidence of growth hormone for patients undergoing abdominal surgery: meta-analysis of randomized controlled trials.

Authors:  Yong Zhou; Xiao-Ting Wu; Gang Yang; Wen Zhuang; Mao-Ling Wei
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

4.  The secretion of human growth hormone stimulated by human growth hormone releasing factor following severe cranio-cerebral trauma.

Authors:  M Gottardis; C Nigitsch; E Schmutzhard; M Neumann; C Putensen; J M Hackl; W Koller
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Exogenous growth hormone: effects on the catabolic response to surgically produced acute stress and on postoperative immune function.

Authors:  R Vara-Thorbeck; J A Guerrero; J Rosell; E Ruiz-Requena; J M Capitán
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

6.  Regulation by fasting of rat insulin-like growth factor I and its receptor. Effects on gene expression and binding.

Authors:  W L Lowe; M Adamo; H Werner; C T Roberts; D LeRoith
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition.

Authors:  T R Ziegler; L S Young; J M Manson; D W Wilmore
Journal:  Ann Surg       Date:  1988-07       Impact factor: 12.969

8.  Decreased serum insulin-like growth factor-I associated with growth failure in newborn lambs with experimental cyanotic heart disease.

Authors:  D Bernstein; J R Jasper; R G Rosenfeld; R L Hintz
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

9.  Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells.

Authors:  S Yamashita; S Melmed
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

10.  Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis.

Authors:  A Caufriez; P Reding; D Urbain; J Golstein; G Copinschi
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.